Paclitaxel
Taxol
Bristol-Myers Squibb Company
NJ
infusion
carboplatin
phase I/II study
patients
non-small cell lung cancer
Carboplatin
fixed target
area
concentration-time curve
Calvert formula
paclitaxel
escalated
patient
dose level I
level
phase II study
level
modification
nonhematologic toxicities
arthralgia
sensory neuropathy
Therapeutic effects
dose
responses
partial
untreated
patients
Toxicities
cohort
patients
phase I trial
paclitaxel
identical
dose
Carboplatin
hematologic toxicities
paclitaxel/carboplatin combination
dosed
weeks
